RESUMO
The effect of local treatment of nostrils with fusidic acid cream was investigated in 30 previously untreated lepromatous leprosy patients. The cream was applied in the nostrils after flushing the nostrils with normal saline, twice a day for a period of four weeks. It was found that 20 mg/gm of sodium fusidate was effective in reducing the morphological index of the nose-blow smear to zero in two weeks in majority of the patients. No untoward side effect was seen in any of the patients. Such nasal treatment along with multidrug therapy may help in reducing the patient's level of infectiousness to their contacts, since the nose is recognized to be an important portal of exit of M. leprae.
Assuntos
Ácido Fusídico/administração & dosagem , Hansenostáticos/administração & dosagem , Hanseníase Virchowiana/tratamento farmacológico , Mycobacterium leprae/efeitos dos fármacos , Administração Intranasal , Adulto , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Quimioterapia Combinada , Feminino , Ácido Fusídico/uso terapêutico , Humanos , Hansenostáticos/uso terapêutico , Hanseníase Virchowiana/microbiologia , Masculino , Mucosa Nasal/microbiologiaRESUMO
Fusidic acid, both systemic and topical, has been used for a wide variety of less common infections. Efficacy for oral fusidic acid has been demonstrated in the treatment of Clostridium difficile colitis and in staphylococcal infections in patients with cystic fibrosis. Topical fusidic acid gel is also effective in bacterial conjunctivitis and other minor external eye infections, and may be effective in reducing bacterial flora in the conjunctival sac prior to eye surgery. Studies suggest a potential role for fusidic acid in neurosurgical prophylaxis, as adjunctive therapy in bacterial endophthalmitis and Legionella pneumonia, and in leprosy. Topical fusidic acid has no effect in the treatment of chlamydial conjunctivitis or the prevention of staphylococcal infections in patients on continuous ambulatory peritoneal dialysis.
Assuntos
Antibacterianos/uso terapêutico , Ácido Fusídico/uso terapêutico , Infecções/tratamento farmacológico , Antibacterianos/administração & dosagem , Clostridioides difficile , Conjuntivite/tratamento farmacológico , Fibrose Cística/complicações , Fibrose Cística/tratamento farmacológico , Endoftalmite/tratamento farmacológico , Enterocolite Pseudomembranosa/tratamento farmacológico , Ácido Fusídico/administração & dosagem , Humanos , Controle de Infecções , Hanseníase Virchowiana/tratamento farmacológico , Neurocirurgia , Soluções Oftálmicas , Diálise Peritoneal Ambulatorial Contínua/efeitos adversos , Pneumonia/tratamento farmacológico , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/etiologiaRESUMO
Clarithromycin(CAM), Roxithromycin(RXM), Minocycline(MINO) and Fosfomycin(FOM) has anti-inflammatory action and immunomodulatory activity, while the anti-mycobacterium leprae activity is shown. CAM and RXM suppress the rat carrageenin edema, and MINO suppresses the rat adjvant arthritis. There is the immunosuppression on adrenocorticosteroid while the inflammatory cytokine is suppressed. CAM, MINO, FOM suppresses the inflammatory cytokine, while it has the immunomodulatory activity. Fusidic acid(FA) suppresses the inflammatory cytokine with the action of being similar to cyclosporin A, and it has the immunomodulatory activity. New macrolides derivatives, CAM and RXM showed the inflammatory regulation, and MINO showed the anti-inflammatory activity with FA. The combination chemotherapy can be enforced, while peripheral neuropathy is prevented by the control of the leprosy reaction.